This inspiring article from Pfizer follows a patient named Eric through his clinical trial journey. For those looking to learn more about the clinical trial process, this is a great resource. “From the thousands of patients who volunteer each year to the scientists, clinicians, and principal investigators (PIs), each individual who contributes to a trial helps to bring about life-changing treatments and advances our knowledge of diseases.” #ClinicalTrials #Patients #Safety #Discovery https://lnkd.in/eUQEb2bn
Prevail InfoWorks’ Post
More Relevant Posts
-
Novartis and Dren Bio Forge New Path in Cancer Treatment with $150M Deal Novartis remains committed to innovation despite past challenges with bispecific antibodies. In a bold move, they've partnered with Dren Bio, Inc. to develop novel bispecific antibodies for cancer. This collaboration leverages Dren Bio's unique Targeted Myeloid Engager and Phagocytosis Platform, designed to activate myeloid cells specifically. Dren Bio secures $150 million upfront, including a $25 million equity investment, with potential milestone payments up to $2.85 billion. If successful, Novartis will handle the drug's development, manufacturing, regulatory affairs, and commercialization. “Our agreement with Dren Bio is a promising opportunity to discover novel bispecific antibody therapies for cancer, building on our longstanding expertise in immuno-oncology science at Novartis,” Shiva Malek, Ph.D., global head of oncology for biomedical research at Novartis, said in the release. What impact do you think this innovative approach will have on cancer treatment? Share your insights on the potential breakthroughs this partnership could bring to the oncology field. Find more details in the article linked in the comments. #Biotechnology #CancerResearch #ImmunoOncology #Novartis #DrenBio #Pharma #Partnership
Novartis hopes for better luck with bispecifics via $150M upfront Dren Bio deal
fiercebiotech.com
To view or add a comment, sign in
-
What!?!? Have you heard about this 180 in insurance? Can you believe those conservative, short-sleeved-shirt insurance company guys at Lloyd's of London have approved the Medical & Commercial International Limited (MCI) Syndicate 1966 to offer insurance for clinical trials using a groundbreaking AI program? What better way to reduce their financial risks in therapeutic drug development than enhancing innovation in the biotech industry using AI technology to forecast clinical trial endpoints? This provides drug developers with insurance coverage to secure clinical trial funding in case of trial failure. With this new insurance model, clinical trial funding becomes more secure, promoting the development of safer and more effective treatments. Do you think there will be more money in biotech investing as a result? "Clinical trial funding insurance is a revolutionary new insurance product with huge unmet demand, and access to Lloyd's will allow MCI to capitalize on this opportunity," said MCI CEO Philip Trafford. "Working side-by-side with lenders and investors, this new program will promote medical innovation and promises a level of risk assessment accuracy unparalleled in the industry." Read more in the article in the comment below. #BiotechInnovation #ClinicalTrials #AI #HealthcareInnovation #InsuranceTech #BiotechFunding #MedicalResearch #PharmaTech #DrugDevelopment #FutureOfMedicine #Biotech #Pharmaceuticals
Medical & Commercial International (MCI) to Utilize GATC Health's AI Platform to Launch World's First Insurance-Backed Program to Finance Clinical Trials
prnewswire.com
To view or add a comment, sign in
-
At Prevail InfoWorks, we prioritize the security and operational continuity of our services. On July 19, a significant outage was detected within our CrowdStrike security infrastructure. We understand the critical nature of such incidents and the potential impact on our stakeholders. Our dedicated tech team immediately mobilized to address the issue. Leveraging their deep expertise and the robust tools at their disposal, they conducted a thorough investigation to identify the root cause of the outage. Within hours, they implemented effective remediation measures, ensuring that all affected systems were restored to full functionality. We are proud of our tech team’s swift and decisive action during this event. Their commitment to maintaining our high standards of security and service reliability has minimized any disruption and safeguarded our operations. We remain dedicated to continuous improvement and are conducting a comprehensive review of this incident to prevent future occurrences. Our focus remains on delivering secure, reliable services to our clients and stakeholders. Thank you for your continued trust and support. Sincerely, Jack Houriet, CEO
To view or add a comment, sign in
-
Shockwave Medical: The Billion-Dollar Game Changer for J&J MedTech Johnson & Johnson's Q2 earnings report highlights their acquisition of Shockwave Medical, set to add $500 million in sales by year-end. In just the first 30 days, Shockwave contributed $77 million, showcasing its immediate impact. Chalk, Borrowed from Shockwave’s website: “In 2009, a marketer, engineer and cardiologist came together to change the nature of interventional therapy for calcified cardiovascular disease. They envisioned a future in which lithotripsy, a trusted technology used to break kidney stones for more than three decades, could be adapted to crack calcium in undilatable lesions in a potentially easier and safer manner. What started out as a crazy idea is now changing the standard of care for patients with calcified disease around the globe.” Have you ever seen a medical device’s revenue ramp up as fast? Share your experience in the comment below. “We closed that transaction in record timing, and we are really excited to shortly announce that they will be the 13th business with sales in excess of $1 billion annually,” added J&J MedTech’s worldwide chairman, Tim Schmid. Find more details in the article linked in the comments. #Biotechnology #HealthcareInnovation #MedTech #JohnsonAndJohnson #ShockwaveMedical #CardiovascularHealth #MedicalAdvancements #HealthcareTech #Innovation #LifeSciences
J&J MedTech pitches Shockwave as its next billion-dollar company in Q2 earnings
fiercebiotech.com
To view or add a comment, sign in
-
Prevail Group Networking and Cocktail Reception Would you like to join us for an evening of networking and engaging conversation? Hosted by Prevail InfoWorks, the full-service CRO & FSP, this event is an excellent opportunity to come together in a relaxed atmosphere to see and be seen. Whether you are in Philadelphia for the AAIC conference or in town for a little fun, please do come by! Located at the lively Ding Feng Tang bar and restaurant on Arch Street between 10th and 11th Avenues, this venue is conveniently situated just 2 blocks from the Pennsylvania Convention Center. Will you be our guest and experience Philly's famous Chinatown with us? More details below. "As we continue our vital work in clinical research, I encourage everyone to join us in Philadelphia for the Alzheimer’s Association International Conference. This event is a unique opportunity to collaborate, share insights, and advance our collective understanding of Alzheimer's disease. Let's gather in this historic city to drive innovation and make a meaningful impact in the fight against Alzheimer's." says Jack Houriet, CEO of Prevail InfoWorks. Event: Prevail Networking and Cocktail Reception Venue: Ding Feng Tang Bar and Restaurant Location: 1021 Arch Street, Philadelphia, PA 19107 Date and Time: Monday, July 29th, 5-8PM RSVP Now: https://lnkd.in/ePFJqtDi #AAIC #Alzheimers #AD #Philly #Philadelphia #PrevailInfoWorks #PrevailPartners #ClinicalDevelopment #ClinicalInnovation #Healthcare #Biotech #Pharma #DingFengTang #Cocktails #Networking
Please fill out this form
https://forms.office.com/pages/forms.office.com
To view or add a comment, sign in
-
'I’ve invented an alternative to uncomfortable smear tests' Sânziana Foia, a bio-engineering PhD student, has revolutionized cervical cancer screening with the creation of Papcup, a non-invasive, at-home test. Inspired by her own uncomfortable experience with traditional smear tests, Sânziana developed this innovative device to detect HPV using menstrual blood. This breakthrough offers women a private, quick, and painless alternative, potentially increasing early cancer detection rates. Backed by the The University of Edinburgh’s Venture Builder Incubator, Sânziana is paving the way for more comfortable and accessible healthcare solutions. Sânziana said: "If someone gets a positive HPV test then they might want to go and get the full smear test for full diagnosis, where they look in depth at what's going on. But we aim to break through that first barrier that women have towards getting their smear test. "We hope to be able to offer women a much more comfortable screening experience." Sânziana told BBC Scotland News: "It's a small device, about the size of my fist. You add to it a sample of menstrual blood that you collect with a swab. Read more in the article in the comment below. #WomenInScience #Innovation #Healthcare #CervicalCancer #HPV #Bioengineering #WomenInSTEM #Papcup #UniversityOfEdinburgh #SânzianaFoia #Diagnostics
'I’ve invented an alternative to uncomfortable smear tests'
bbc.com
To view or add a comment, sign in
-
More This Week on Women in BIO Women leaders are driving innovation in biotech, navigating today's challenging funding environment and leveraging AI in drug discovery. Alethia Young, CFO of Bicycle Therapeutics, emphasizes the need for aggressive strategies to secure funding, while Sherrie Glass, Biopharma Strategy and Business Development Leader at Bristol Myers Squibb, highlights the importance of investing in late-stage assets to sustain revenue growth. Their leadership is crucial in shaping the future of biopharma, where AI and strategic investment are set to revolutionize the industry. Just as you will find in the Prevail model. “Biotech assets are ultimately the “lifeblood” of the biopharma pipeline; and biopharma has the firepower and the money to invest in these candidates.” explained Sherrie Glass. Read more in the article in the comment below and visit: prevailinfoworks.com #Biotech #WomenInLeadership #AI #DrugDevelopment #Innovation #Pharma #HealthcareInnovation #Biopharma #InvestmentStrategies #Leadership
AI and stable funding environments are catalysts for biotech assets - Pharmaceutical Technology
pharmaceutical-technology.com
To view or add a comment, sign in
-
Empowering Women in Biotech: Pioneering Cancer Treatments with Caitlyn Miller, CEO of TwoStep Therapeutics Women in Biotech: Caitlyn Miller, PhD CEO of TwoStep Therapeutics, has leveraged her childhood experiences with cancer to drive pioneering advancements in targeted therapies, shaping the future of oncology. Inspired by personal hardship, Caitlyn co-founded TwoStep to revolutionize solid tumor treatment through innovative drug delivery platforms. With a recent $6.5 million seed round, TwoStep is poised to expand its pipeline of tumor-targeting therapies, leveraging PIP, a novel peptide developed for precise and effective treatment delivery. Caitlyn's leadership highlights the pivotal role of women in biotech, driving forward transformative solutions in healthcare. How can we empower more women to lead? “What really drew me into the field of tumor-targeted therapies was seeing that we could design better drugs that would only kill the tumor tissue, but not the healthy tissue,” says Caityln Miller, CEO of TwoStep Therapeutics. Read more in the article in the comment below. #WomenInBiotech #BiotechInnovation #PrecisionMedicine #TargetedTherapies #CancerTreatment #OncologyAdvancements #WomenLeaders #HealthcareInnovation #DrugDelivery #StartupLife #STEMWomen
Bertozzi's TwoStep Therapeutics to Target Solid Tumors With Engineered Peptide Drug Delivery Vehicle
genengnews.com
To view or add a comment, sign in
-
Breaking Barriers: Coco Brown - Empowering Women to Lead in Boardrooms Worldwide! Women in Business: Coco Brown, PhD, CEO of Athena Alliance, has transformed her early career in tech into a mission-driven path dedicated to empowering women in leadership roles. Inspired by her experiences and driven by the mission to overcome imposter syndrome, Coco has steered Athena Alliance to support over 450 women in securing board roles. What advice would you give to women aspiring to leadership roles in today's competitive business landscape?" “Think much bigger about yourself. What if I could be the CEO? What if I could start investing in companies? And through that, advising on things I care about, and through that, becoming a board member? And what if I could start my own company? Don't limit your thinking,” says Coco. “Make sure you understand where you fit in this landscape so that you can build a real strategy for it, the way kids build a strategy to get into the school they want. That's a big secret to success.” Read more in the article in the comment below. #WomenInLeadership #BoardDiversity #EmpowerWomen #LeadershipDevelopment #ImposterSyndrome #CorporateEquality #InclusiveLeadership #AthenaAlliance #DiverseBoards #StrategicLeadership
How This CEO Is Helping More Women Land Board Positions By Breaking Through Self-Limiting Beliefs
social-www.forbes.com
To view or add a comment, sign in
This is a great piece